The priming activities of human IFN-c~, IFN-/? and IFN-? were compared on the same antiviral basis using human buffy coat leukocytes stimulated with Sendai virus or concanavalin A (Con A) to produce 1FN-~ or IFN-y, respectively. Pretreatment of leukocytes with any type of IFN enhanced their IFN-c~ and IFN-y production, but IFN-c~ and IFN-/~ had more potent priming activities than IFN-y. IFN-c~ and IFN-? did not potentiate the priming activity of each other in either the IFN-cc-or the IFN-?-producing system. Pretreatment of leukocytes with relatively high doses of IFN-c¢ or
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Short communication (11) and IFN-~, (A) on the production of IFN-cc (a) and . Leukocytes were suspended in Eagle's MEM containing 2 mg/ml human gamma-globulinfree human serum. Cell concentrations for IFN-a and IFN-7 production were 1 × 10~/ml and 2.5 × 107/ml, respectively. Leukocytes were pretreated with IFNs for 2 h (a) or 4 h (b) prior to stimulation with 400 HAU/ml Sendai virus (a) or 15 rtg/ml Con A (b). Antiviral activities of the supernatants were determined on WISH cells 16 h after induction. Values are averages of four independent experiments. In two cases, IFN titres in the supernatants of the IFN-~-treated leukocytes were measured in MDBK cells to determine the trace of priming IFN remaining after three washing cycles (E]). 1 x l06 IU/mg protein by chromatography on Controlled Pore Glass (CPG-75) beads (ElectroNucleonics, Fairfield, N.J., U.S.A.) and molecular sieving on Sephacryl S-200 (Pharmacia). In some cases these preparations were further purified by immunoaffinity chromatography to asp. act. of 3 x 107 IU/mg protein. The IFN-v was produced in concanavalin A (Con A)-stimulated leukocyte cultures and purified to asp. act. of 1 x 105 U/mg protein by chromatography on CPG-75 beads.
Following the priming, leukocytes were washed three times with Hanks' balanced salt solution and stimulated with 400 haemagglutination units (HAU) per ml Sendai virus (B61fidi et al., 1980) or with 15 lag/ml Con A (Calbiochem) to produce IFN-~ or IFN-v, respectively. Antiviral activity was assayed on human amnion (WISH and WK), human diploid fibroblast, monkey kidney (CV-1), or bovine kidney (MDBK) cells. Titres of IFN-~ and IFN-y preparations were expressed in IU/ml and U/ml; they were calibrated with NIH human leukocyte IFN reference reagent G-023-901-527. At the end of this work a human IFN-y reference reagent (NIH Gg23-901-530) became available. In our test 1 U of IFN-~, correspond to 0.43 reference U.
To compare the three known IFN types for their effectiveness in the enhancement of IFN-a production, we treated leukocyte cultures with IFNs at various concentrations and stimulated them with Sendai virus (Fig. 1 a) . IFN-c~ and IFN-fl caused dose-dependent increases in IFN-a production, which reached a maximum of twice the basal level after treatment with 100 to 300 IU/ml. A similar effect was achieved only with 10-to 15-fold times more IFN-y. There was no significant difference in the IFN titres using 2, 4 or 6 h IFN pretreatment periods (data not shown).
We also compared the efficacies of the three IFN types in the enhancement of IFN-v production of Con A-stimulated leukocytes (Fig. 1 b) . Similarly IFN-y production was enhanced in a dose-dependent manner by IFN pretreatment, and IFN-c~ and IFN-fl showed more potent priming activities than IFN-7. The IFN-~ production was doubled by very low doses of IFN-a or IFN-fl (3 to 7 IU/ml). Pretreatment of leukocytes with relatively high doses of IFN-~ or IFN-fl (1000 to 3000 IU/ml) caused a very efficient enhancement (more than 40-fold) of IFN-y production, revealing the possibility of producing IFN-y with a high titre. The length of the priming period (between 2 and 6 h) had no effect on the priming efficiency of the IFNs. Using longer priming periods the titres were decreased (data not shown). Since a similar priming effect was achieved with IFN-cc purified to asp. act. of 1 x 100 IU/mg protein and IFN-~ purified by immunoaffinity chromatography to asp, act. of 3 x l0 T IUlmg protein, it seems that the IFN itself, and not other contaminants, is responsible for the priming effect. The high antiviral titres in the supernatants of the primed cultures were not due to the potentiation of the IFN-y which was produced by the trace of IFN used for priming (see Fig. 1 b) since addition of a specific antiserum to IFN-~ in excess to a culture producing IFN-7 in IFN-~-pretreated leukocytes did not decrease the IFN titre produced (data not shown). The properties of the IFN produced by primed and Con A-induced leukocytes were identical to those of IFN-y (Langford et al., 1979; Blalock et al., 1980; Rubin & Gupta, 1980; Van Damme et al., 1983) , since 80 to 90% of its antiviral activity was sensitive at pH 2, and it protected only cell lines of human origin against vesicular stomatitis virus (VSV). Development of its antiviral activity on WISH cells was much slower than that of IFN-cc It possessed a higher anticellular activity than those of IFN-~ and IFN-/7, and it had a mol. wt. of 51000 (data not shown).
It has recently been shown that IFN-~ or IFN-fl and IFN-y can potentiate each other in terms of their antiviral (Fleischmann et al., 1979) , anti-tumour (Fleischmann et al., 1980) and immunoregulatory (Weigent et al., 1983) activities. We therefore investigated whether mixed IFN preparations (IFN-cc + IFN-7) enhanced IFN production more effectively than a single type (IFN-c~ or IFN-~,) . Since the priming potency of IFN-~ was much more pronounced than that of IFN-y, the question was whether IFN-v can enhance the priming activity of IFN-cc Our results showed that the IFN-a and IFNg, production of leukocytes pretreated with a mixture of IFN-c~ and IFN-y did not exceed the level for IFN-~-treated cells with the same antiviral activity (Fig.  2a, b) ; so in our systems we could not detect any potentiation. However, in WISH cells the antiviral activities of these preparations were potentiated by a factor of 5 to 10 at a 1 : 1 ratio (100 units each) in the VSV yield reduction test (data not shown).
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